No record found
No record found
capitalstake.com. Provided by * Returns not adjusted for payouts
^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.
Company Profile
BF Biosciences Limited ("BFBL", "Company", or the "Issuer") was incorporated as an unlisted public limited company under the Companies Ordinance, 1984 (now Companies Act, 2017) in 2006, and operates within the pharmaceutical industry. BFBL is a 80%:20% joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina. The Company's core operations involve the import, manufacturing, marketing and distribution of pharmaceutical products.
| Akhter Khalid Waheed | CEO |
| Sebastian Martin Ferrarassi | Chairperson |
| Abdur Rehman | Company Secretary |
CDC Share Registrar Services Limited, CDC House, 99-B, Block-B, S.M.C.H.S, Main Shahrah Faisal, Karachi
KPMG Taseer Hadi & Co. Chartered Accountants
Equity Profile
Announcements
| Date | Title | Document |
|---|---|---|
| Oct 30, 2025 | Transmission of Quarterly Financial Statements for the Period Ended 30-09-2025 | View PDF |
| Oct 27, 2025 | Financial Results for the Quarter Ended 2025-09-30 | View PDF |
| Oct 21, 2025 | Annual Progress Report for the Year Ended June 30, 2025 | View PDF |
| Oct 3, 2025 | Transmission of Annual Financial Statements for the Year Ended 30-06-2025 | View PDF |
| Sep 23, 2025 | Financial Results for the Year Ended 30-06-2025 | View PDF |
| Date | Title | Document |
|---|---|---|
| Oct 27, 2025 | Certified true copy of the resolutions passed in the Annual General Meeting of the Company | View PDF |
| Oct 17, 2025 | Board Meeting | View |
| Oct 3, 2025 | Notice of Annual General Meeting | View PDF |
| Oct 2, 2025 | Notice of Annual General Meeting prior to publication | View PDF |
| Sep 15, 2025 | Board Meeting | View |
| Date | Title | Document |
|---|---|---|
| Nov 20, 2025 | Corporate Briefing Session - Presentation | View PDF |
| Nov 18, 2025 | Corporate Briefing Session | View PDF |
| Oct 14, 2025 | Material Information | View PDF |
| Oct 13, 2025 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Apr 17, 2025 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Financials
All numbers in thousands (000's) except EPS
| 2025 | 2024 | |
|---|---|---|
| Sales | 5,837,466 | 3,658,720 |
| Profit after Taxation | 447,147 | 385,413 |
| EPS | 5.52 | 6.09 |
| Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|
| Sales | 2,432,294 | 1,500,469 | 1,327,202 | 1,386,372 |
| Profit after Taxation | 159,521 | 124,527 | 80,539 | 115,273 |
| EPS | 1.81 | 1.59 | 1.09 | 1.82 |

Ratios
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Gross Profit Margin (%) | 39.19 | 41.89 | |
| Net Profit Margin (%) | 7.66 | 10.53 | |
| EPS Growth (%) | (9.36) | ||
| PEG | (3.27) |









Feedback
Terms of Use
https://www.psx.com.pk